3//SEC Filing
APTAFIN S P A 3
Accession 0001213900-21-037494
CIK 0000707511other
Filed
Jul 18, 8:00 PM ET
Accepted
Jul 19, 4:15 PM ET
Size
7.4 KB
Accession
0001213900-21-037494
Insider Transaction Report
Form 3
APTAFIN S P A
Other
Holdings
Common Stock Warrant (right to buy)
Exercise: $0.24From: 2021-06-30Exp: 2023-06-30→ Common Stock (1,125,000 underlying)- 1,500,000
Common Stock
Common Stock Warrant (right to buy)
Exercise: $0.28From: 2021-06-30Exp: 2026-06-30→ Common Stock (1,125,000 underlying)
Footnotes (2)
- [F1]On June 30, 2021, in a private placement by the issuer, Aptafin S.p.A. ("Aptafin") entered into a purchase agreement, pursuant to which it agreed to purchase 1,500,000 shares of the common stock of the issuer and warrants to acquire the issuer's common stock, for an aggregate purchase price of $300,000. Aptafin is filing this Form 3 as it has now been able to regenerate the necessary Edgar codes. A Form 4 with respect to this transaction was filed by Paolo Cavazza on July 2, 2021. Mr. Cavazza owns 99% of the equity interests of Apta Finance SA, which in turn owns 100% of the equity interests of Aptafin. Mr. Cavazza may be deemed to indirectly beneficially own the securities of the issuer purchased by Aptafin.
- [F2]Aptafin received two different warrants in the transaction, one of which is exercisable, in whole or in part, at any time and from time to time, from June 30, 2021 through June 30, 2023, for up to 1,125,000 shares of common stock of the issuer at an exercise price of $0.24 per share, and one of which is exercisable, in whole or in part, at any time and from time to time, from June 30, 2021 through June 30, 2026, for up to 1,125,000 shares of common stock of the issuer at an exercise price of $0.28 per share.
Documents
Issuer
REGENERX BIOPHARMACEUTICALS INC
CIK 0000707511
Entity typeother
Related Parties
1- filerCIK 0001232942
Filing Metadata
- Form type
- 3
- Filed
- Jul 18, 8:00 PM ET
- Accepted
- Jul 19, 4:15 PM ET
- Size
- 7.4 KB